High Flow Nasal Cannula in Immediately Post Extubation (HFNC)

March 1, 2019 updated by: Hospital Italiano de Buenos Aires

Evaluation of Results of the Application of High Flow Nasal Cannula to Prevent the Failure of Extubation

The aim of the study is to determine the incidence of failure of extubation in high-risk patients using High Flow Nasal Cannula (HFNC) to prevent such failure in the Intensive Care Unit. A prospective cohort study was performed. To all adult patients receiving invasive mechanical ventilation ≥ 48 hours and ready for scheduled extubation according to tolerance of spontaneous breathing trial, with at least one of the criteria for high-risk for extubation failure (age greater than 65 years, hypoxemic acute respiratory failure as a cause of invasive mechanical ventilation, > 1 spontaneous ventilation test failed consecutive, history of chronic heart failure, history of chronic obstructive pulmonary disease or PaCO2> 45 mmHg, body mass index >30 kg/m2, post-operative solid organ transplantation), HFNC is applied for 24 hours. Demographic variables and clinical and gasometric parameters at the end of the spontaneous breathing trial, at 60 minutes, at 6 and 24 hours after the start of HFNC are recorded.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

At the end of the successful spontaneous breathing trial, clinical and gasometric parameters will be recorded and extubation will be performed. HFNC is placed with a flow of 50 l / m (only the flow is reduced before intolerance, at 5 l / min but only up to 40 l / min). Inspiratory oxygen fraction (FiO2) initially at 1 and progressively decreases until pulse oximeter saturation (SpO2) ≥ 92% is achieved. Said configuration is maintained for 60 minutes. After this time, arterial blood samples are taken and clinical and gasometric parameters are recorded in the follow-up chart. Based on them, behavior to be followed is defined. If "Fault criteria" are presented, a higher ventilatory support will be initiated. If not, continue with HFNC for the next 23 hours without exception. In this period the initial flow is maintained (40 to 50 l / min) and the FiO2 is programmed according to the SpO2 objective (≥ 92%). At 6 o'clock a new clinical and gasometric evaluation and data loading is carried out. 24 hours after the start of HFNC, a blood gas sample is taken and clinical and gasometric parameters are recorded. Treatment with HFNC is only suspended if the "Failure criteria" or the "Interruption criteria" are met. In the presence of the "Failure Criteria" and prior to delivering a greater ventilatory support, the clinical and gasometric parameters are recorded in the spreadsheet.

The data of categorical variables will be presented as frequency and percentage, while in quantitative variables, after testing normality by Shapiro-Wilks test, they will be presented as mean and standard deviation or median and interquartile range depending on their distribution. For comparisons between groups, chi-square or Fisher tests will be used, depending on the frequency expected in discrete and categorical variables, and in the continuous T or Mann-Whitney tests, depending on the type of distribution and variance. To determine the factors of risk of failure to extubation, a logistic regression study will be carried out with a system of selection of variables by forward steps. The odds ratio and its 95% confidence intervals will be calculated. Variables that are significant in the univariate study (p value <0.2) will be included in the multiple logistic regression study.

Study Type

Observational

Enrollment (Actual)

165

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Buenos Aires, Argentina, C1181ACH
        • Hospital Italiano de Buenos Aires

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

All adult patients receiving invasive mechanical ventilation ≥48 hours and ready for scheduled extubation according to tolerance of spontaneous breathing trial.

Description

Inclusion criteria:

- All adult patients receiving invasive mechanical ventilation ≥48 hours and ready for scheduled extubation according to tolerance of spontaneous breathing trial, with at least one of the following criteria for high-risk for extubation failure:

  • Age greater than 65 years.
  • Hypoxemic acute respiratory failure as a cause of invasive mechanical ventilation.
  • >1 spontaneous ventilation test failed consecutive.
  • History of chronic heart failure.
  • History of chronic obstructive pulmonary disease or PaCO2 >45 mmHg.
  • Body mass index >30 kg/m2.
  • Post-operative solid organ transplantation.

Exclusion criteria:

  • Need for orotracheal intubation and invasive mechanical ventilation (IOT / AVMI) according to the decision of the attending physician.
  • Deterioration of the state of consciousness determined by Kelly Matthay's Scale >3.
  • Hemodynamic instability: systolic blood pressure (TAS) <90 mmHg or TAM <65 mmHg despite receiving fluids and/ or vasopressors.
  • Neuromuscular disease
  • Neurocritical pathology.
  • Epistaxis
  • Skull base fracture, or inability to fix the HFNC.
  • History of obstructive sleep apnea-hypopnea syndrome with indication and use of nocturnal continuous positive pressure.
  • Participation in another research protocol of HFNC.

Elimination criteria

. Directives before or after the onset of a disease that limits the therapeutic effort and indicates not to intubate or perform cardiopulmonary resuscitation.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Extubation failure
Time Frame: In the first 48 hours
the need to discontinue treatment with HFNC to progress to invasive or non-invasive ventilatory support within 48 hours of extubation.
In the first 48 hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Time to failure of extubation
Time Frame: In the first 48 hours
the date and time of extubation and start of HFNC will be recorded as well as the date and time of discontinuation of HFNC to progress to another type of ventilatory support within 48 hours following extubation.
In the first 48 hours
Reasons for extubation failure
Time Frame: In the first 48 hours
the cause of extubation failure
In the first 48 hours
Type of ventilatory support post-failure of extubation
Time Frame: In the first 48 hours
the type of ventilatory support post-failure will be recorded. Non-invasive mechanical ventilatory. Intubation orotracheal and invasive mechanical ventilatory.
In the first 48 hours
Average time of use the HFNC
Time Frame: Through study completion, an average of 1 year
the total hours of use of HFNC will be recorded
Through study completion, an average of 1 year
Length of stay in the Intensive care unit
Time Frame: Through study completion, an average of 1 year
the total number of days of stay in the Intensive care unit will be recorded.
Through study completion, an average of 1 year
Incidence of mortality in the Intensive care unit
Time Frame: Through study completion, an average of 1 year
the relationship between the total number of patients requiring HFNC and those who died after being included in the study will be recorded.
Through study completion, an average of 1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Paulina E Ezcurra, Lic
  • Principal Investigator: Maria S Venuti, Dr

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

December 1, 2016

Primary Completion (ACTUAL)

January 3, 2019

Study Completion (ACTUAL)

January 3, 2019

Study Registration Dates

First Submitted

March 28, 2018

First Submitted That Met QC Criteria

April 11, 2018

First Posted (ACTUAL)

April 12, 2018

Study Record Updates

Last Update Posted (ACTUAL)

March 4, 2019

Last Update Submitted That Met QC Criteria

March 1, 2019

Last Verified

March 1, 2019

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Airway Extubation

Clinical Trials on high flow nasal cannula

3
Subscribe